国家医疗保障局办公室关于基本医保药品目录内 中药饮片部分名称变更的通知 各省、自治区、直辖市及新疆生产建设兵团医疗保障局: 近期,2025年版《中国药典》中部分中药饮片名称发生了变 更。为做好 2025年版基本医保药品目录的落地工作,维护参保患 者用药的连续性,我局对照《中国药典》,对基本医保药品目录内 部分名称修改的饮片进行了标注,名称变更不影响相应饮片的支付 类型。现将基本医保药品目录内基金予以支付和不予支付的中药饮 片在新版药典中的名称变更情况印发给你们。请遵照执行。 附件:1. 基金予以支付的中药饮片在新版药典中名称变更 2. 基金不予支付的中药饮片在新版药典中名称变更 国家医疗保障局办公室 2026年1月27日 (主动公开) 附件 1 基金予以支付的中药饮片在新版药典中名称变更 | 序号 | 目录内中药饮片名称 | 2025年版《中国药典》变更后名称 | | --- | --- | --- | | 1 | 白芥子 | 芥子 | | N | 陈皮 | 陈皮(不含广陈皮) | | 3 | 党参片 | 党参 | | 4 | 地黄 | 生地黄 | | 5 | 甘草片 | 甘草 | | ー | H TH | ...

Core Insights - The new basic medical insurance drug list has been officially implemented since January 1, 2026, with many insured individuals already purchasing newly added drugs from medical institutions [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the basic medical insurance drug list, with over half of these drugs already recorded in sales at medical institutions [1] - The drug Tirzepatide injection, used for treating adult type 2 diabetes, has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug Icosapent ethyl injection, known for its "half-yearly injection" regimen, has been recorded in sales at 400 medical institutions [1] Group 2: Access and Information - Insured individuals can check the availability of insured drugs at medical institutions through the "National Medical Insurance Negotiated Drug Supply Institution List" on the National Medical Insurance Service Platform [1]